AIM
CERE

Aigen Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Aigen Investment Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,215
Closed -$348K – 1081
2023
Q4 		$348K Buy
+8,215
New +$236K 0.06% 445

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Aigen Investment Management's CERE Position: Q1 2024 in Review

Aigen Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 8,215 shares — an estimated $348K sold.

Aigen Investment Management first reported a position in CERE in Q4 2023 and held it in 1 quarter. The position peaked at $348K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Aigen Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Aigen Investment Management sold 8,215 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $348K.
  • Aigen Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Aigen Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $348K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.